Continuous ruxolitinib therapy extends survival over that seen with best available therapy in patients with myelofibrosis and also provides durable reductions in splenomegaly, according to results released at the 18th Congress of the European Hematology Association .
http://www.medicalnewstoday.com/articles/262671.php
http://www.medicalnewstoday.com/articles/262671.php
No comments:
Post a Comment